Kits
Bone Sialoprotein (BSP) ELISA
Kits
Description
Bone sialoprotein (BSP) is a phosphorylated glycoprotein that comprises 12% of the
total non-collagenous proteins in bone and is thought to be involved in bone mineralisation
and remodelling. The polypeptide chain of BSP has a molecular weight of
35kDa. Native BSP has an apparent molecular weight of 70–80kDa due to complex
posttranslational modifications involving glycosylation. BSP is synthesized mainly by
skeletal-associated cell types, including fibroblasts, hypertrophic chondrocytes, osteoblasts,
osteocytes, osteoclasts, as well as trophoblasts.
BSP is overexpressed and underglycosylated in human primary breast and prostate
cancers that metastasize to the bone, whereby BSP expression correlates with the
development of microcalcifications. Underglycosylated BSP is also expressed by other
tumours, such as lung cancer, thyroid cancer, multiple myeloma and neuroblastoma,
that predominantly metastasise to bones.
total non-collagenous proteins in bone and is thought to be involved in bone mineralisation
and remodelling. The polypeptide chain of BSP has a molecular weight of
35kDa. Native BSP has an apparent molecular weight of 70–80kDa due to complex
posttranslational modifications involving glycosylation. BSP is synthesized mainly by
skeletal-associated cell types, including fibroblasts, hypertrophic chondrocytes, osteoblasts,
osteocytes, osteoclasts, as well as trophoblasts.
BSP is overexpressed and underglycosylated in human primary breast and prostate
cancers that metastasize to the bone, whereby BSP expression correlates with the
development of microcalcifications. Underglycosylated BSP is also expressed by other
tumours, such as lung cancer, thyroid cancer, multiple myeloma and neuroblastoma,
that predominantly metastasise to bones.